Data as of 2:38pm ET
| -0.07 / -1.05%|
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Its lead product candidate, the ARX-01 Sufentanil NanoTab(TM) PCA System, which has completed Phase 2 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA) which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. The company's other products include; ARX-02 for the treatment of cancer breakthrough pain, ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office and ARX-04, designed to provide a non-invasive, fast-onset treatment of moderate-to-severe acute pain in patients with trauma or injury. AcelRx Pharmaceuticals was founded by Thomas A. Schreck and Pamela P. Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
|Richard A. King||President, Chief Executive Officer & Director|
|Timothy E. Morris||Chief Financial Officer|
|Pamela Pierce Palmer||Director & Chief Medical Officer|
|Mark A. Evashenk||Vice President-Clinical Operations|
|Lawrence G. Hamel||Chief Development Officer|